Back to search results

Undifferentiated Connective Tissue Disease Registry

This registry aims to better understand undifferentiated connective tissue disease (UCTD), a condition where you have symptoms of a connective tissue disease but don't meet the full criteria for a specific one. Researchers will collect information from your medical records and ask you questions about your symptoms, like joint pain or rashes. This information will help them learn more about how UCTD affects people and predict if it might progress to other conditions like lupus. You may be able to join if you are 18 or older, are a patient of an HSS rheumatologist, have certain positive blood tests (like ANA or anti-ds DNA), and experience symptoms of connective tissue disease. The study will look at changes in your quality of life, fatigue, and depression over three years.

Study design
This is an observational study, meaning researchers will collect information without giving any new treatments. The study plans to enroll 100 participants.
What's involved
Researchers will collect information from your medical records, including your health history, physical exams, and lab results. You will also be asked questions about your symptoms.
Compensation
Not stated in the trial record.
Follow-up
The study will track changes in your health and well-being for three years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02234388

Undifferentiated Connective Tissue Disease Registry

Recruiting
Not specifiedAges 18+Observational
Hospital for Special Surgery, New York
~100 participants
Updated 2026-02-12 on ClinicalTrials.gov
What's tested:Observation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in SF-36 Score
Measured over 3 years
+3 more outcomes measured

Conditions

Undifferentiated Connective Tissue Disease

Explore related trials

Undifferentiated Connective Tissue Disease60 kDa SS-A/Ro Ribonucleoproteinanti-ds DNAAntinuclear AntibodyAutoantibody

Where it's being run

1 sites across 1 states
New York1

Who to contact

Lucy Masto, BS
[email protected]
917-260-4968
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Any patient under the care of an HSS rheumatologist
Positive ANA or a positive anti-ds DNA, anti-Ro/SS-A or other autoantibody on 2 or more occasions at least 12 weeks apart
One or more signs or symptoms of connective tissue disease, including but not limited to arthralgia, arthritis, myalgia, rash, sicca symptoms, pericarditis, pleuritis, pulmonary symptoms, peripheral neuropathy, photosensitivity, alopecia, oral or nasal ulcers, leucopenia, anemia, and abnormal nailfold capillaroscopy

Exclusion

Patients who meet criteria for well defined CTD including SLE, rheumatoid arthritis, polymyositis or dermatomyositis, systemic sclerosis, or antiphospholipid syndrome
Patients who are less than 18
Those unable to give informed consent in English

What this trial measures

  • Change in SF-36 Score3 years

    Patient questionnaire that measures health-related quality of life.

  • Change in Fatigue Severity Scale Score3 years

    Evaluates the impact of fatigue on the patient.

  • Change in Beck Depression Inventory Score3 years

    Self-reported depression severity questionnaire

  • Connective Tissue Disease Criteria3 years

    The physician will monitor which characteristics from each connective tissue disease the patient presents with. This will show how UCTD progresses and what the most prominent characteristics of the disease are.